BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, van Geer MA, van Beusechem VW, Kaspers GJ, van Royen BJ, Jiménez CR, Helder MN. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer 2013;109:2142-54. [PMID: 24064975 DOI: 10.1038/bjc.2013.578] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Lin Z, Wu Z, Luo W. Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma. Cancers (Basel) 2021;13:4469. [PMID: 34503279 DOI: 10.3390/cancers13174469] [Reference Citation Analysis]
2 He Y, Ma J, Ye X. A support vector machine classifier for the prediction of osteosarcoma metastasis with high accuracy. Int J Mol Med 2017;40:1357-64. [PMID: 28901446 DOI: 10.3892/ijmm.2017.3126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
3 Bourseau-Guilmain E, Menard JA, Lindqvist E, Indira Chandran V, Christianson HC, Cerezo Magaña M, Lidfeldt J, Marko-Varga G, Welinder C, Belting M. Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells. Nat Commun 2016;7:11371. [PMID: 27094744 DOI: 10.1038/ncomms11371] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
4 Aliyandi A, Zuhorn IS, Salvati A. Disentangling Biomolecular Corona Interactions With Cell Receptors and Implications for Targeting of Nanomedicines. Front Bioeng Biotechnol 2020;8:599454. [PMID: 33363128 DOI: 10.3389/fbioe.2020.599454] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xu H, Mei Q, Shi L, Lu J, Zhao J, Fu Q. Tumor-Suppressing Effects of miR451 in Human Osteosarcoma. Cell Biochem Biophys 2014;69:163-8. [DOI: 10.1007/s12013-013-9783-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
6 Hingorani P, Missiaglia E, Shipley J, Anderson JR, Triche TJ, Delorenzi M, Gastier-Foster J, Wing M, Hawkins DS, Skapek SX. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clin Cancer Res 2015;21:4733-9. [PMID: 26473193 DOI: 10.1158/1078-0432.CCR-14-3326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Song Z, Pearce MC, Jiang Y, Yang L, Goodall C, Miranda CL, Milovancev M, Bracha S, Kolluri SK, Maier CS. Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities. Sci Rep 2020;10:727. [PMID: 31959767 DOI: 10.1038/s41598-019-56878-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
8 Wang SY, Hu HZ, Qing XC, Zhang ZC, Shao ZW. Recent advances of drug delivery nanocarriers in osteosarcoma treatment. J Cancer 2020;11:69-82. [PMID: 31892974 DOI: 10.7150/jca.36588] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
9 Wylie PG, Onley DJ, Hammerstein AF, Bowen WP. Advances in Laser Scanning Imaging Cytometry for High-Content Screening. ASSAY and Drug Development Technologies 2015;13:66-78. [DOI: 10.1089/adt.2014.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
10 Greenfield EM, Collier CD, Getty PJ. Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update. Adv Exp Med Biol 2020;1258:141-55. [PMID: 32767239 DOI: 10.1007/978-3-030-43085-6_9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Roy J, Wycislo KL, Pondenis H, Fan TM, Das A. Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine origin. PLoS One 2017;12:e0183930. [PMID: 28910304 DOI: 10.1371/journal.pone.0183930] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
12 Wagner F, Holzapfel BM, Martine LC, Mcgovern J, Lahr CA, Boxberg M, Prodinger PM, Grässel S, Loessner D, Hutmacher DW. A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma. Acta Biomaterialia 2019;89:372-81. [DOI: 10.1016/j.actbio.2019.02.051] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
13 Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther 2021;28:321-34. [PMID: 32873870 DOI: 10.1038/s41417-020-00221-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chaiyawat P, Settakorn J, Sangsin A, Teeyakasem P, Klangjorhor J, Soongkhaw A, Pruksakorn D. Exploring targeted therapy of osteosarcoma using proteomics data. Onco Targets Ther 2017;10:565-77. [PMID: 28203090 DOI: 10.2147/OTT.S119993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
15 Ségaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol 2015;4:1-12. [PMID: 26579483 DOI: 10.1016/j.jbo.2015.01.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 11.3] [Reference Citation Analysis]
16 Pereira-Silva M, Alvarez-Lorenzo C, Concheiro A, Santos AC, Veiga F, Figueiras A. Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. Eur J Pharm Biopharm 2020;148:88-106. [PMID: 31958514 DOI: 10.1016/j.ejpb.2019.10.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
17 Mori F, Sacconi A, Canu V, Ganci F, Novello M, Anelli V, Covello R, Ferraresi V, Muti P, Biagini R, Blandino G, Strano S. miR-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget 2015;6:13946-61. [PMID: 26062442 DOI: 10.18632/oncotarget.3539] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
18 Ross E, Ata R, Thavarajah T, Medvedev S, Bowden P, Marshall JG, Antonescu CN. AMP-Activated Protein Kinase Regulates the Cell Surface Proteome and Integrin Membrane Traffic. PLoS One 2015;10:e0128013. [PMID: 26010094 DOI: 10.1371/journal.pone.0128013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
19 Park JA, Cheung NV. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J Hematol Oncol 2020;13:172. [PMID: 33303017 DOI: 10.1186/s13045-020-01012-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
20 Li Y, Qin H, Ye M. An overview on enrichment methods for cell surface proteome profiling. J Sep Sci 2020;43:292-312. [PMID: 31521063 DOI: 10.1002/jssc.201900700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 DeRenzo C, Gottschalk S. Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. Adv Exp Med Biol 2020;1257:109-31. [PMID: 32483735 DOI: 10.1007/978-3-030-43032-0_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Kuhlmann L, Cummins E, Samudio I, Kislinger T. Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Review of Proteomics 2018;15:259-75. [DOI: 10.1080/14789450.2018.1429924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
23 Liu J, Wu S, Xie X, Wang Z, Lei Q. Identification of potential crucial genes and key pathways in osteosarcoma. Hereditas 2020;157:29. [PMID: 32665038 DOI: 10.1186/s41065-020-00142-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Gobin B, Moriceau G, Ory B, Charrier C, Brion R, Blanchard F, Redini F, Heymann D. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PLoS One 2014;9:e90795. [PMID: 24599309 DOI: 10.1371/journal.pone.0090795] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
25 Mancarella C, Morrione A, Scotlandi K. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options. Cells 2021;10:2075. [PMID: 34440844 DOI: 10.3390/cells10082075] [Reference Citation Analysis]
26 Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, De Boer JP, Zandieh-doulabi B, Forouzanfar T, Helder MN. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment. Pharm Res 2017;34:2891-900. [DOI: 10.1007/s11095-017-2272-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
27 Haghiralsadat F, Amoabediny G, Helder MN, Naderinezhad S, Sheikhha MH, Forouzanfar T, Zandieh-Doulabi B. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery. Artif Cells Nanomed Biotechnol 2018;46:169-77. [PMID: 28376641 DOI: 10.1080/21691401.2017.1304403] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
28 Riedl SJ, Pasquale EB. Targeting the Eph System with Peptides and Peptide Conjugates. Curr Drug Targets 2015;16:1031-47. [PMID: 26212263 DOI: 10.2174/1389450116666150727115934] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
29 Wagner F, Holzapfel BM, McGovern JA, Shafiee A, Baldwin JG, Martine LC, Lahr CA, Wunner FM, Friis T, Bas O, Boxberg M, Prodinger PM, Shokoohmand A, Moi D, Mazzieri R, Loessner D, Hutmacher DW. Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma. Biomaterials 2018;171:230-46. [PMID: 29705656 DOI: 10.1016/j.biomaterials.2018.04.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
30 Heffner KM, Hizal DB, Kumar A, Shiloach J, Zhu J, Bowen MA, Betenbaugh MJ. Exploiting the proteomics revolution in biotechnology: from disease and antibody targets to optimizing bioprocess development. Curr Opin Biotechnol 2014;30:80-6. [PMID: 24997444 DOI: 10.1016/j.copbio.2014.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]